The importance of protein kinase A in prostate cancer: relationship to patient outcome in Radiation Therapy Oncology Group trial 92-02.
Clin. Cancer Res., Sep;15(17):5478-84 (2009)
Phase III multi-institutional trial of adjuvant chemotherapy with paclitaxel, estramustine, and oral etoposide combined with long-term androgen suppression therapy and radiotherapy versus long-term androgen suppression plus radiotherapy alone for high-ris
Int. J. Radiat. Oncol. Biol. Phys., Mar;73(3):672-8 (2009)
Prognostic value of p16 in locally advanced prostate cancer: a study based on Radiation Therapy Oncology Group Protocol 9202.
J. Clin. Oncol., Jul;25(21):3082-9 (2007)
Whole-pelvis, "mini-pelvis," or prostate-only external beam radiotherapy after neoadjuvant and concurrent hormonal therapy in patients treated in the Radiation Therapy Oncology Group 9413 trial.
Int. J. Radiat. Oncol. Biol. Phys., Nov;66(3):647-53 (2006)
Androgen suppression adjuvant to definitive radiotherapy in prostate carcinoma--long-term results of phase III RTOG 85-31.
Int. J. Radiat. Oncol. Biol. Phys., Apr;61(5):1285-90 (2005)
Failure patterns by prognostic group determined by recursive partitioning analysis (RPA) of 1547 patients on four radiation therapy oncology group (RTOG) studies in inoperable nonsmall-cell lung cancer (NSCLC).
Int. J. Radiat. Oncol. Biol. Phys., Sep;42(2):263-7 (1998)
Survival results among patients with alpha-fetoprotein-positive, unresectable hepatocellular carcinoma: analysis of three sequential treatments of the RTOG and Johns Hopkins Oncology Center.
Cancer J Sci Am., 4(3):178-84 (1998 May-Jun)
Impact of surgical staging in evaluating the radiotherapeutic outcome in RTOG #77-06, a phase III study for T1BN0M0 (A2) and T2N0M0 (B) prostate carcinoma.
Int. J. Radiat. Oncol. Biol. Phys., Mar;40(4):769-82 (1998)
Impact of adding concurrent chemotherapy to hyperfractionated radiotherapy for locally advanced non-small cell lung cancer (NSCLC): comparison of RTOG 83-11 and RTOG 91-06.
Am. J. Clin. Oncol., Oct;20(5):435-40 (1997)
Influence of an oligodendroglial component on the survival of patients with anaplastic astrocytomas: a report of Radiation Therapy Oncology Group 83-02.
Int. J. Radiat. Oncol. Biol. Phys., Jul;38(5):911-4 (1997)
Racial differences in prostate-specific antigen levels in patients with local-regional prostate cancer.
Prostate., Apr;31(1):42-6 (1997)
Development of anemia and recovery in prostate cancer patients treated with combined androgen blockade and radiotherapy.
Prostate., Oct;29(4):243-8 (1996)
Deglycosylation of serum vitamin D3-binding protein leads to immunosuppression in cancer patients.
Cancer Res., Jun;56(12):2827-31 (1996)
Recursive partitioning analysis of 2105 patients treated in Radiation Therapy Oncology Group studies of head and neck cancer.
Cancer., May;77(9):1905-11 (1996)
Race and prognosis of brain tumor patients entering multicenter clinical trials. A report from the Radiation Therapy Oncology Group.
Am. J. Clin. Oncol., Apr;19(2):114-20 (1996)
Late effects of hyperfractionated radiotherapy for advanced head and neck cancer: long-term follow-up results of RTOG 83-13.
Int. J. Radiat. Oncol. Biol. Phys., Jun;32(3):577-88 (1995)
White matter changes are correlated significantly with radiation dose. Observations from a randomized dose-escalation trial for malignant glioma (Radiation Therapy Oncology Group 83-02).
Cancer., Nov;74(10):2828-35 (1994)
Treatment related sequelae following external beam radiation for prostate cancer: a review with an update in patients with stages T1 and T2 tumor.
J. Urol., Nov;152(5 Pt 2):1799-805 (1994)
PSA confirmation of cure at 10 years of T1B, T2, N0, M0 prostate cancer patients treated in RTOG protocol 7706 with external beam irradiation.
Int. J. Radiat. Oncol. Biol. Phys., Sep;30(2):289-92 (1994)
Patterns of Care and RTOG studies in prostate cancer: long-term survival, hazard rate observations, and possibilities of cure.
Int. J. Radiat. Oncol. Biol. Phys., Jan;28(1):39-45 (1994)